Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Septerna Inc (SEPN)

Septerna Inc (SEPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Mon Mar 9, 3:05PM CDT

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026  Advancing SEP-479...

SEPN : 24.18 (-0.41%)
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy GlobeNewswire - Sun Mar 1, 8:45AM CST

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily  Well-Tolerated Across All...

SEPN : 24.18 (-0.41%)
Septerna to Present at TD Cowen 46th Annual Health Care Conference GlobeNewswire - Tue Feb 24, 7:00AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Feb 10, 3:05PM CST

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting GlobeNewswire - Tue Feb 10, 7:00AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer GlobeNewswire - Thu Jan 8, 3:05PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Dec 17, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)
Septerna to Participate in 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results GlobeNewswire - Mon Nov 10, 2025

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million...

SEPN : 24.18 (-0.41%)
Septerna to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 24.18 (-0.41%)

Barchart Exclusives

Elon Musk Is Still a ‘Huge Admirer’ of Jensen Huang and Plans to Keep Buying Nvidia Chips. Does That Make NVDA Stock a Buy on the Dip? Barchart - Sat Mar 21, 11:00AM CDT
Musk’s comments ease concerns about Nvidia losing major AI customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.